#160 - Paul Offit, M.D.: The latest on COVID-19 vaccines and their safety, herd immunity, and viral variants

May 3, 2021

Dr. Paul Offit, a pediatrician and vaccine development expert, dives into the current landscape of COVID-19 vaccines, debunking myths surrounding mRNA safety. He discusses the immune responses from vaccination versus natural infection and the implications for herd immunity. Offit also addresses the challenges posed by new viral variants and the origins of SARS-CoV-2. The conversation emphasizes future preparedness for potential outbreaks and the ethical responsibilities of healthcare providers in ensuring vaccine access and addressing hesitancy.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Relative vs. Absolute Risk Reduction

The press often misrepresents vaccine efficacy by focusing on relative risk reduction instead of absolute risk reduction.
The J&J vaccine had lower relative risk reduction but higher absolute risk reduction than mRNA vaccines.

ADVICE

Risk Assessment

Assess both the risks and benefits of medical interventions, using absolute risk reduction rather than relative risk reduction.
Consider the number needed to treat (NNT) to prevent a negative outcome when making decisions.

INSIGHT

Vaccine Hesitancy

Pausing the J&J vaccine, while intended to address safety concerns, could increase vaccine hesitancy.
Vaccine hesitancy is a major obstacle to achieving herd immunity.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Paul Offit is a pediatrician specializing in infectious diseases and an expert in virology and vaccine development. He currently serves on the FDA committee evaluating COVID-19 vaccines. In this episode, Paul's second appearance on The Drive, he provides an update on all the SARS-CoV-2 vaccines currently deployed, explains why the concerns raised around the mRNA vaccines are not legitimate, and offers his view on the prospects and timeframe of reaching herd immunity. He also takes a deep dive into immunology, explaining the short-term and long-term immune response to both natural infection and vaccination and how these two can function together to provide durable immunity. Additionally, they discuss the theories on the origins of this virus, what impact the new COVID-19 variants might have, and the recent pausing of the J&J vaccine. Finally, they discuss how we can be better prepared for an inevitable future outbreak of a novel virus. This episode was originally recorded on April 14, 2021.

We discuss:

Overview and current status of the SARS-CoV-2 vaccine strategies [4:10];
Addressing concerns about mRNA vaccines [9:00];
How the failure to make an effective HIV vaccine aided the development of a COVID-19 vaccine [16:45];
Where SARS-CoV-2 falls on the spectrum of its ability to mutate and what that means for immunity and vaccination [21:30];
How the combination of short-term and long-term immune response to SARS-CoV-2 work together to provide durable immunity [28:00];
Importance of understanding relative vs. absolute risk reduction [38:15];
Implications of pausing the J&J vaccine due to reports of blood clotting in the brain [42:45];
What constitutes herd immunity and the concerns of rising vaccine hesitancy [47:45];
When we might reach herd immunity, future vaccines for children, and long-term outlook for maintaining population immunity [58:45];
Theories about the origins of SARS-CoV-2 [1:07:00];
Preparing for the possibility of a future pandemic and how we can learn from our mistakes [1:10:40]; and
More.

Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/pauloffit2 Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.